Skip to content Skip to footer

Celgene News

HomeAll PostsCelgene News

Nucleai Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts

Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over

sun pharmaceutical industries: Sun Pharma gets USFDA nod to market generic medication

BMS Collaboration Paying Off for Exscientia

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Celgene, Acceleron alum Backstrom tapped to be the top purveyor at Scholar Rock

Bristol Myers loses bid to toss $6.4B CVR lawsuit tied to Celgene takeover, Breyanzi approval

BMS Dives into AI Deal with Exscientia that Could Hit $1.2 Billion

Mental health in the workplace, saved by bots and apps?